Literature DB >> 22367385

The outcome of allogeneic hematopoietic stem cell transplants without total body irradiation in pediatric patients with acute lymphoblastic leukemia: single centre experience.

Amir Hamidieh1, Mona Kargar, Mohammad Jahani, Kamran Alimoghaddam, Babak Bahar, Seyed Asadollah Mousavi, Masoud Iravani, Arash Jalali, Mahdi Jalili, Ardeshir Ghavamzadeh.   

Abstract

The most widely accepted conditioning regimen to allogeneic hematopoietic stem cell transplantation consists of total body irradiation, especially in patients affected by acute lymphoblastic leukemia (ALL). In this retrospective study, we report our experience on hematopoietic stem cell transplantation in 44 pediatric patients with acute lymphoblastic leukemia using a non-radiation-based conditioning regimen (busulfan/cyclophosphamide). Median age at transplantation was 12.5 years (range, 4 to 14 y). 39 out of 44 patients received transplants in complete remission. At a median follow-up of 390 days, the probabilities of 3-year disease-free survival and overall survival were 50% and 68%, respectively. Disease status of hematopoietic stem cell transplantation was the only significant variable affecting the overall survival. Acute and chronic graft-versus-host disease occurred in 23 (64%) and 12(18%) patients, respectively. Relapse was significantly higher among patients transplanted in advanced disease status. The results of the study indicate that non-radiation-based preparative regimens can be used in pediatric patients with ALL. However, well-designed comparative trials are needed to better clarify the difference between radiation and non-radiation-based conditioning regimens in pediatric ALL.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22367385     DOI: 10.1097/MPH.0b013e31824435a1

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  5 in total

1.  Prognostic factors and outcomes for pediatric patients receiving an haploidentical relative allogeneic transplant using CD3/CD19-depleted grafts.

Authors:  M A Diaz; A Pérez-Martínez; B Herrero; N Deltoro; I Martinez; M Ramirez; L Abad; J Sevilla; E Merino; J Ruiz; J L Vicario; M Gonzalez-Vicent
Journal:  Bone Marrow Transplant       Date:  2016-04-18       Impact factor: 5.483

2.  Hematopoietic SCT in Iranian children 1991-2012.

Authors:  A A Hamidieh; M Behfar; A E S Babaki; A Jalali; A-S Hosseini; M Jahani; K Alimoghaddam; A Ghavamzadeh
Journal:  Bone Marrow Transplant       Date:  2015-01-19       Impact factor: 5.483

3.  Factors Associated with Long-Term Risk of Relapse after Unrelated Cord Blood Transplantation in Children with Acute Lymphoblastic Leukemia in Remission.

Authors:  Kristin M Page; Myriam Labopin; Annalisa Ruggeri; Gerard Michel; Cristina Diaz de Heredia; Tracey O'Brien; Alessandra Picardi; Mouhab Ayas; Henrique Bittencourt; Ajay J Vora; Jesse Troy; Carmen Bonfim; Fernanda Volt; Eliane Gluckman; Peter Bader; Joanne Kurtzberg; Vanderson Rocha
Journal:  Biol Blood Marrow Transplant       Date:  2017-04-21       Impact factor: 5.742

4.  Haploidentical hematopoietic stem cell transplantation without total body irradiation for pediatric acute leukemia: a single-center experience.

Authors:  Yanshun Mu; Maoquan Qin; Bin Wang; Sidan Li; Guanghua Zhu; Xuan Zhou; Jun Yang; Kai Wang; Wei Lin; Huyong Zheng
Journal:  Onco Targets Ther       Date:  2016-05-02       Impact factor: 4.147

5.  Myeloablative conditioning for allo-HSCT in pediatric ALL: FTBI or chemotherapy?-A multicenter EBMT-PDWP study.

Authors:  Andre Manfred Willasch; Christina Peters; Petr Sedláček; Jean-Hugues Dalle; Vassiliki Kitra-Roussou; Akif Yesilipek; Jacek Wachowiak; Arjan Lankester; Arcangelo Prete; Amir Ali Hamidieh; Marianne Ifversen; Jochen Buechner; Gergely Kriván; Rose-Marie Hamladji; Cristina Diaz-de-Heredia; Elena Skorobogatova; Gérard Michel; Franco Locatelli; Alice Bertaina; Paul Veys; Sophie Dupont; Reuven Or; Tayfun Güngör; Olga Aleinikova; Sabina Sufliarska; Mikael Sundin; Jelena Rascon; Ain Kaare; Damir Nemet; Franca Fagioli; Thomas Erich Klingebiel; Jan Styczynski; Marc Bierings; Kálmán Nagy; Manuel Abecasis; Boris Afanasyev; Marc Ansari; Kim Vettenranta; Amal Alseraihy; Alicja Chybicka; Stephen Robinson; Yves Bertrand; Alphan Kupesiz; Ardeshir Ghavamzadeh; Antonio Campos; Herbert Pichler; Arnaud Dalissier; Myriam Labopin; Selim Corbacioglu; Adriana Balduzzi; Jacques-Emmanuel Galimard; Peter Bader
Journal:  Bone Marrow Transplant       Date:  2020-03-17       Impact factor: 5.483

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.